ImmunityBio Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ImmunityBio and certain executives, alleging that false or misleading statements made between January 19, 2026, and March 24, 2026, led to investor losses.
- False Statements: The lawsuit claims that Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding ImmunityBio's business and operations, causing investor damages when the truth emerged.
- Investor Eligibility: Investors who purchased ImmunityBio common stock during the class period and suffered losses are encouraged to contact Block & Leviton to learn how to seek recovery, with a deadline of May 26, 2026, for lead plaintiff applications.
- Whistleblower Program: Individuals with non-public information about ImmunityBio are encouraged to assist in the investigation or file a report with the SEC, with potential rewards of up to 30% of any successful recovery for whistleblowers.
Trade with 70% Backtested Accuracy
Analyst Views on IBRX
About IBRX
About the author
IMMUNITYBIO INC PLANS TO FILE SUPPLEMENTAL BLA BY 2026
Community Bio Initiative: The initiative focuses on submitting supplemental information to enhance community engagement and support.
Contractual Framework: The project is structured under a contract that outlines the responsibilities and expectations for all parties involved.
Timeline for Submission: The goal is to have all supplemental materials submitted by the year 2026.
Impact on Local Development: The initiative aims to foster local development and improve community resources through collaborative efforts.
IBRX Stock Rebounds: Anktiva Shifts Focus to Severe Pneumonia Following Successful Bladder Cancer Trial Milestone
Bladder Cancer Study Update: A Phase 3 bladder cancer study has reached a key efficacy endpoint, prompting a review by an independent monitoring committee. The trial is comparing a combination therapy of Anktiva and BCG against BCG alone in newly diagnosed patients.
Stock Performance: Shares of Immunity Bio (IBRX) surged by about 9% following the announcement of new trials and progress in their bladder cancer study, recovering from a previous sharp sell-off.
New Trials for Severe Pneumonia: Immunity Bio has initiated new studies evaluating Anktiva in combination with off-the-shelf immune cell therapy for critically ill patients with severe pneumonia, aiming to improve immune function and survival rates.
Market Sentiment: Retail sentiment for IBRX has shifted positively, with significant increases in message volumes, indicating growing investor interest and optimism about the company's potential in cancer therapies.
ImmunityBio Shares Decline Following FDA Alert: Drug Not Capable of 'Treating All Cancers.'
- FDA Action: The Food and Drug Administration (FDA) accused ImmunityBio of using false or misleading advertising for its bladder cancer drug, Anktiva.
- Market Reaction: Following the FDA's announcement, shares of ImmunityBio experienced a significant decline.
ImmunityBio Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ImmunityBio and certain executives, alleging that false or misleading statements made between January 19, 2026, and March 24, 2026, led to investor losses.
- False Statements: The lawsuit claims that Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding ImmunityBio's business and operations, causing investor damages when the truth emerged.
- Investor Eligibility: Investors who purchased ImmunityBio common stock during the class period and suffered losses are encouraged to contact Block & Leviton to learn how to seek recovery, with a deadline of May 26, 2026, for lead plaintiff applications.
- Whistleblower Program: Individuals with non-public information about ImmunityBio are encouraged to assist in the investigation or file a report with the SEC, with potential rewards of up to 30% of any successful recovery for whistleblowers.
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
IMMUNITYBIO INC PLANS TO FILE SUPPLEMENTAL BLA BY 2026
Community Bio Initiative: The initiative focuses on submitting supplemental information to enhance community engagement and support.
Contractual Framework: The project is structured under a contract that outlines the responsibilities and expectations for all parties involved.
Timeline for Submission: The goal is to have all supplemental materials submitted by the year 2026.
Impact on Local Development: The initiative aims to foster local development and improve community resources through collaborative efforts.
IBRX Stock Rebounds: Anktiva Shifts Focus to Severe Pneumonia Following Successful Bladder Cancer Trial Milestone
Bladder Cancer Study Update: A Phase 3 bladder cancer study has reached a key efficacy endpoint, prompting a review by an independent monitoring committee. The trial is comparing a combination therapy of Anktiva and BCG against BCG alone in newly diagnosed patients.
Stock Performance: Shares of Immunity Bio (IBRX) surged by about 9% following the announcement of new trials and progress in their bladder cancer study, recovering from a previous sharp sell-off.
New Trials for Severe Pneumonia: Immunity Bio has initiated new studies evaluating Anktiva in combination with off-the-shelf immune cell therapy for critically ill patients with severe pneumonia, aiming to improve immune function and survival rates.
Market Sentiment: Retail sentiment for IBRX has shifted positively, with significant increases in message volumes, indicating growing investor interest and optimism about the company's potential in cancer therapies.
ImmunityBio Shares Decline Following FDA Alert: Drug Not Capable of 'Treating All Cancers.'
- FDA Action: The Food and Drug Administration (FDA) accused ImmunityBio of using false or misleading advertising for its bladder cancer drug, Anktiva.
- Market Reaction: Following the FDA's announcement, shares of ImmunityBio experienced a significant decline.
ImmunityBio Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ImmunityBio and certain executives, alleging that false or misleading statements made between January 19, 2026, and March 24, 2026, led to investor losses.
- False Statements: The lawsuit claims that Patrick Soon-Shiong materially overstated Anktiva's capabilities, resulting in materially false and misleading statements regarding ImmunityBio's business and operations, causing investor damages when the truth emerged.
- Investor Eligibility: Investors who purchased ImmunityBio common stock during the class period and suffered losses are encouraged to contact Block & Leviton to learn how to seek recovery, with a deadline of May 26, 2026, for lead plaintiff applications.
- Whistleblower Program: Individuals with non-public information about ImmunityBio are encouraged to assist in the investigation or file a report with the SEC, with potential rewards of up to 30% of any successful recovery for whistleblowers.
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
